Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 2/2010

01-02-2010 | Letter to the Editor

Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma

Authors: Masataka Hosoi, Go Yamamoto, Yoichi Imai, Mineo Kurokawa

Published in: Annals of Hematology | Issue 2/2010

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM (2004) Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 77(1):72–76CrossRefPubMed
2.
Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM (2001) Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 12(9):1327–1329CrossRefPubMed
3.
Haefner MD, Siciliano RD, Widmer LA, Vogel Wigger BM, Frick S (2007) Reversibleposterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie 30(3):138–140CrossRefPubMed
Metadata
Title
Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma
Authors
Masataka Hosoi
Go Yamamoto
Yoichi Imai
Mineo Kurokawa
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/2010
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-009-0783-x

Other articles of this Issue 2/2010

Annals of Hematology 2/2010 Go to the issue

Erratum

Long-term response to deferiprone therapy in Asian Indians

Original Article

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

Letter to the Editor

Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant)

Original Article

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

Original Article

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

Letter to the Editor

A case of generalized MALT lymphoma with IgM paraproteinemia and peripheral blood involvement
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits